Navigation überspringen
Universitätsbibliothek Heidelberg
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Goldschmidt, Hartmut [VerfasserIn]   i
 Bärtsch, Marc-Andrea [VerfasserIn]   i
 Schlenzka, Jana [VerfasserIn]   i
 Becker, Natalia [VerfasserIn]   i
 Habermehl, Christina [VerfasserIn]   i
 Hielscher, Thomas [VerfasserIn]   i
 Raab, Marc-Steffen [VerfasserIn]   i
 Hillengaß, Jens [VerfasserIn]   i
 Sauer, Sandra [VerfasserIn]   i
 Müller-Tidow, Carsten [VerfasserIn]   i
 Luntz, Steffen P. [VerfasserIn]   i
 Jauch, Anna [VerfasserIn]   i
 Hose, Dirk [VerfasserIn]   i
 Seckinger, Anja [VerfasserIn]   i
 Brossart, Peter [VerfasserIn]   i
 Goerner, Martin [VerfasserIn]   i
 Klein, Stefan [VerfasserIn]   i
 Schmidt-Hieber, Martin [VerfasserIn]   i
 Reimer, Peter [VerfasserIn]   i
 Graeven, Ullrich [VerfasserIn]   i
 Fenk, Roland [VerfasserIn]   i
 Haenel, Mathias [VerfasserIn]   i
 Martin, Hans [VerfasserIn]   i
 Lindemann, Hans W. [VerfasserIn]   i
 Scheid, Christoph [VerfasserIn]   i
 Nogai, Axel [VerfasserIn]   i
 Salwender, Hans [VerfasserIn]   i
 Noppeney, Richard [VerfasserIn]   i
 Besemer, Britta [VerfasserIn]   i
 Weisel, Katja [VerfasserIn]   i
Titel:Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma
Titelzusatz:the randomized GMMG phase III trial ReLApsE
Verf.angabe:Hartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, Natalia Becker, Christina Habermehl, Thomas Hielscher, Marc-Steffen Raab, Jens Hillengass, Sandra Sauer, Carsten Müller-Tidow, Steffen Luntz, Anna Jauch, Dirk Hose, Anja Seckinger, Peter Brossart, Martin Goerner, Stefan Klein, Martin Schmidt-Hieber, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Hans Martin, Hans W. Lindemann, Christoph Scheid, Axel Nogai, Hans Salwender, Richard Noppeney, Britta Besemer, Katja Weisel
E-Jahr:2020
Jahr:21 July 2020
Umfang:11 S.
Fussnoten:Gesehen am 28.07.2020
Titel Quelle:Enthalten in: Leukemia
Ort Quelle:London : Springer Nature, 1997
Jahr Quelle:2021
Band/Heft Quelle:35(2021), 4, Seite 1134-1144
ISSN Quelle:1476-5551
Abstract:The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase III, multicenter trial randomized patients with 1st-3rd relapse of multiple myeloma (MM) to a transplant arm (n = 139) consisting of 3 Rd (lenalidomide 25 mg, day 1-21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles) reinduction cycles, sHDCT (melphalan 200 mg/m2), ASCT, and lenalidomide maintenance (10 mg/day) or to a control arm (n = 138) of continuous Rd. Median PFS was 20.7 months in the transplant and 18.8 months in the control arm (HR 0.87; 95% CI 0.65-1.16; p = 0.34). Median OS was not reached in the transplant and 62.7 months in the control arm (HR 0.81; 95% CI 0.52-1.28; p = 0.37). Forty-one patients (29%) did not receive the assigned sHDCT/ASCT mainly due to early disease progression, adverse events, and withdrawal of consent. Multivariate landmark analyses from the time of sHDCT showed superior PFS and OS (p = 0.0087/0.0057) in patients who received sHDCT/ASCT. Incorporation of sHDCT/ASCT into relapse treatment with Rd was feasible in 71% of patients and did not significantly prolong PFS and OS on ITT analysis while patients who received sHDCT/ASCT may have benefitted.
DOI:doi:10.1038/s41375-020-0948-0
URL:Volltext: https://doi.org/10.1038/s41375-020-0948-0
 Volltext: https://www.nature.com/articles/s41375-020-0948-0
 DOI: https://doi.org/10.1038/s41375-020-0948-0
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1725647060
Verknüpfungen:→ Zeitschrift
 
 
Lokale URL UB: Zum Volltext

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68621315   QR-Code
zum Seitenanfang